{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:34:35Z","timestamp":1770064475252,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11255-019-02329-5","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T13:02:38Z","timestamp":1574686958000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria"],"prefix":"10.1007","volume":"52","author":[{"given":"Liu","family":"Xiaowei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Bo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-8511","authenticated-orcid":false,"given":"Zhang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"25","key":"2329_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368(25):2402\u20132414","journal-title":"N Engl J Med"},{"issue":"6","key":"2329_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1172\/JCI109998","volume":"66","author":"ME Conley","year":"1980","unstructured":"Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Investig 66(6):1432\u20131436","journal-title":"J Clin Investig"},{"issue":"5","key":"2329_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0272-6386(88)80022-2","volume":"12","author":"JC Jennette","year":"1988","unstructured":"Jennette JC (1988) The immunohistology of IgA nephropathy. Am J Kidney Dis 12(5):348\u2013352","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2329_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrneph.2012.58","volume":"8","author":"KN Lai","year":"2012","unstructured":"Lai KN (2012) Pathogenesis of IgA nephropathy. Nat Rev Nephrol 8(5):275\u2013283","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2329_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000045563","volume":"84","author":"J Mera","year":"2000","unstructured":"Mera J, Uchida S, Nagase M (2000) Clinicopathologic study on prognostic markers in IgA nephropathy. Nephron 84(2):148\u2013157","journal-title":"Nephron"},{"issue":"6","key":"2329_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.ajkd.2012.02.326","volume":"59","author":"SJ Barbour","year":"2012","unstructured":"Barbour SJ, Reich HN (2012) Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 59(6):865\u2013873","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2329_CR7","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18(12):3177\u20133183","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2329_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1440-1797.2007.00898.x","volume":"13","author":"J Lv","year":"2008","unstructured":"Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H (2008) Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology 13(3):242\u2013246","journal-title":"Nephrology"},{"issue":"2","key":"2329_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ncpneph1015","volume":"5","author":"JC Velez","year":"2009","unstructured":"Velez JC (2009) The importance of the intrarenal renin\u2013angiotensin system. Nat Clin Pract Nephrol 5(2):89\u2013100","journal-title":"Nat Clin Pract Nephrol"},{"issue":"4","key":"2329_CR10","first-page":"508","volume":"19","author":"C Pozzi","year":"2006","unstructured":"Pozzi C, Del Vecchio L, Casartelli D et al (2006) ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J Nephrol 19(4):508\u2013514","journal-title":"J Nephrol"},{"issue":"2","key":"2329_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10157-011-0545-7","volume":"16","author":"T Moriyama","year":"2012","unstructured":"Moriyama T, Nakayama K, Ochi A et al (2012) Comparison of inhibitors of renin\u2013angiotensin\u2013aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol 16(2):231\u2013237","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"2329_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient. Kidney Int 82(8):840\u2013856","journal-title":"Kidney Int"},{"issue":"1","key":"2329_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie FW, Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13(1):142\u2013148","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2329_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/07853890.2016.1153805","volume":"48","author":"JH Shin","year":"2016","unstructured":"Shin JH, Lee JE, Park JH et al (2016) The effects of cytotoxic therapy in progressive IgA nephropathy. Ann Med 48(3):171\u2013181","journal-title":"Ann Med"},{"issue":"7","key":"2329_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrneph.2017.65","volume":"13","author":"RJ Glassock","year":"2017","unstructured":"Glassock RJ (2017) Glomerular disease: targeted steroid therapy for IgA nephropathy. Nat Rev Nephron 13(7):390\u2013392","journal-title":"Nat Rev Nephron"},{"issue":"4","key":"2329_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1440-1797.2004.00255.x","volume":"9","author":"JA Samuels","year":"2004","unstructured":"Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA (2004) Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrol 9(4):177\u2013185","journal-title":"Nephrol"},{"issue":"2","key":"2329_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2169\/internalmedicine.52.8323","volume":"52","author":"T Moriyama","year":"2013","unstructured":"Moriyama T, Iwasaki C, Tanaka K et al (2013) Effects of combination therapy with renin\u2013angiotensin system inhibitors and eicosapentaenoic acid on IgA nephropathy. Intern Med 52(2):193\u2013199","journal-title":"Intern Med"},{"issue":"2","key":"2329_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cei.12823","volume":"186","author":"FM Rasche","year":"2016","unstructured":"Rasche FM, Keller F, Rasche WG et al (2016) Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol 186(2):115\u2013133","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2329_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0961203307085879","volume":"17","author":"M Cutolo","year":"2008","unstructured":"Cutolo M, Otsa K (2008) Review: vitamin D, immunity and lupus. Lupus 17(1):6\u201310","journal-title":"Lupus"},{"issue":"14","key":"2329_CR20","doi-asserted-by":"publisher","first-page":"15896","DOI":"10.1073\/pnas.0803751105","volume":"105","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105(14):15896\u201315901","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2329_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","volume":"54","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54(4):647\u2013652","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2329_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ki.2010.22","volume":"77","author":"DK Deb","year":"2010","unstructured":"Deb DK, Sun T, Wong KE et al (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77(11):1000\u20131009","journal-title":"Kidney Int"},{"issue":"5","key":"2329_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","volume":"51","author":"CC Szeto","year":"2008","unstructured":"Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK (2008) Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 51(5):724\u2013731","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2329_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","volume":"59","author":"LJ Liu","year":"2012","unstructured":"Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY (2012) Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 59(1):67\u201374","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2329_CR25","first-page":"694","volume":"74","author":"J Berger","year":"1968","unstructured":"Berger J, Hinglais N (1968) Intercapillary deposits of IgA\u2013IgG. J Urol Nephrol 74(9):694\u2013695","journal-title":"J Urol Nephrol"},{"issue":"6","key":"2329_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5414\/CNP71617","volume":"71","author":"KT Woo","year":"2009","unstructured":"Woo KT, Chan CM, Tan HK et al (2009) Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol 71(6):617\u2013624","journal-title":"Clin Nephrol"},{"issue":"2","key":"2329_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3904\/kjim.2014.266","volume":"31","author":"YI Jo","year":"2016","unstructured":"Jo YI, Na HY, Moon JY et al (2016) Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J Intern Med 31(2):335\u2013343","journal-title":"Korean J Intern Med"},{"issue":"12","key":"2329_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861\u2013869","journal-title":"N Engl J Med"},{"issue":"4","key":"2329_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","volume":"15","author":"RA Rodby","year":"2000","unstructured":"Rodby RA, Rohde RD, Clarke WR et al (2000) The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 15(4):487\u2013497","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2329_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.ajkd.2007.04.015","volume":"50","author":"IH De Boer","year":"2007","unstructured":"De Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS (2007) 25-Hydroxyvitamin D levels and albuminuria in the third national health and nutrition examination survey (NHANES III). Am J Kidney Dis 50(1):69\u201377","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2329_CR31","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1681\/ASN.2007060666","volume":"19","author":"X Tan","year":"2008","unstructured":"Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19(9):1741\u20131752","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2329_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease. Ann Intern Med 148(1):30\u201348","journal-title":"Ann Intern Med"},{"key":"2329_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2369-13-150","volume":"13","author":"L De Nicola","year":"2012","unstructured":"De Nicola L, Conte G, Russo D, Gorini A, Minutolo R (2012) Anti-proteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin\u2013angiotensin system: a prospective observational study. BMC Nephrol 13:150. https:\/\/doi.org\/10.1186\/1471-2369-13-150","journal-title":"BMC Nephrol"},{"issue":"6","key":"2329_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1681\/ASN.2009080872","volume":"21","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Kong J, Deb DK, Chang A, Li YC (2010) Vitamin D receptor attenuates renal fibrosis by suppressing the renin\u2013angiotensin system. J Am Soc Nephrol 21(6):966\u2013973","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2329_CR35","doi-asserted-by":"publisher","first-page":"F1212","DOI":"10.1152\/ajprenal.00002.2009","volume":"296","author":"DK Deb","year":"2009","unstructured":"Deb DK, Chen Y, Zhang Z et al (2009) 1, 25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 296(5):F1212\u2013F1218","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"2329_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1083\/jcb.200102028","volume":"154","author":"HG Palmer","year":"2001","unstructured":"Palmer HG, Gonzalez-Sancho JM, Espada J et al (2001) Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154(2):369\u2013387","journal-title":"J Cell Biol"},{"issue":"12","key":"2329_CR37","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1681\/ASN.2006050520","volume":"17","author":"X Tan","year":"2006","unstructured":"Tan X, Li Y, Liu Y (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17(12):3382\u20133393","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2329_CR38","first-page":"363","volume":"8","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wu X, Xiong L et al (2014) Role of vitamin D3 in regulation of T helper cell 17 and regulatory T cell balance in rats with immunoglobulin A nephropathy. Iran J Kidney Dis 8(5):363\u2013370","journal-title":"Iran J Kidney Dis"},{"issue":"6 Suppl","key":"2329_CR39","first-page":"1704S","volume":"125","author":"JM Lemire","year":"1995","unstructured":"Lemire JM, Archer DC, Beck L, Spiegelberg HL (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125(6 Suppl):1704S\u20131708S","journal-title":"J Nutr"},{"issue":"2","key":"2329_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0162-3109(91)90015-Q","volume":"21","author":"K M\u00fcller","year":"1991","unstructured":"M\u00fcller K, Heilmann C, Poulsen LK, Barington T, Bendtzen K (1991) The role of monocytes and T cells in 1, 25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. Immunopharmacol 21(2):121\u2013128","journal-title":"Immunopharmacol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-019-02329-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:12:02Z","timestamp":1659085922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-019-02329-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02329-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"25 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies were got approval from the Ethics Committee of XiJing hospital affiliated to Fourth Military Medical University (clinical trial registration number XJ20070047) according to the 1964 Helsinki Declaration and its latter amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was signed from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}